Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?

The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in term...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraccioli, Gianfranco, Tolusso, Barbara, Gremese, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890326/
https://www.ncbi.nlm.nih.gov/pubmed/27255529
http://dx.doi.org/10.1186/s13075-016-1022-1
_version_ 1782435104196395008
author Ferraccioli, Gianfranco
Tolusso, Barbara
Gremese, Elisa
author_facet Ferraccioli, Gianfranco
Tolusso, Barbara
Gremese, Elisa
author_sort Ferraccioli, Gianfranco
collection PubMed
description The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized.
format Online
Article
Text
id pubmed-4890326
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48903262016-06-03 Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons? Ferraccioli, Gianfranco Tolusso, Barbara Gremese, Elisa Arthritis Res Ther Editorial The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology (ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in the first 6 months. A possible alternative can be hypothesized. BioMed Central 2016-06-02 2016 /pmc/articles/PMC4890326/ /pubmed/27255529 http://dx.doi.org/10.1186/s13075-016-1022-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Editorial
Ferraccioli, Gianfranco
Tolusso, Barbara
Gremese, Elisa
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
title Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
title_full Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
title_fullStr Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
title_full_unstemmed Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
title_short Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
title_sort could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890326/
https://www.ncbi.nlm.nih.gov/pubmed/27255529
http://dx.doi.org/10.1186/s13075-016-1022-1
work_keys_str_mv AT ferraccioligianfranco couldweusealowerdoseofrituximabtotreatrheumatoidarthritisinclinicalpracticeprosandcons
AT tolussobarbara couldweusealowerdoseofrituximabtotreatrheumatoidarthritisinclinicalpracticeprosandcons
AT gremeseelisa couldweusealowerdoseofrituximabtotreatrheumatoidarthritisinclinicalpracticeprosandcons

Ejemplares similares